Novel therapies for hypereosinophilic syndromes.

S A Antoniu

Journal: The Netherlands journal of medicine 2011;68(1):304-10

PMID: 20739727

Free Full Text on van Zuiden Communications View on PubMed

Abstract

BACKGROUND

Conventional therapies (corticosteroids, cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition.

OBJECTIVE

To review the novel therapies for HES discussing their advantages and shortcomings.

METHODS AND RESULTS

Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.

CONCLUSION

Some of the novel therapies might become appropriate therapeutic options for HES.

Address: Division of Pulmonary Disease, University of Medicine and Pharmacy Gr.T.Popa, Iasi, Romania. [email protected]

Link outs

Free resources

Full Text Sources:

http://www.njmonline.nl/njm/getarticle.php?v=68&i=...

Medical:

https://medlineplus.gov/steroids.html

MeSH Terms: Adrenal Cortex Hormones, Alemtuzumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Antigens, CD, Antigens, Neoplasm, Antineoplastic Agents, Benzamides, Benzenesulfonates, Bone Marrow Transplantation, CD52 Antigen, Glycoproteins, Humans, Hypereosinophilic Syndrome, Imatinib Mesylate, Immunologic Factors, Interferon-alpha, Interleukin-5, Niacinamide, Phenylurea Compounds, Piperazines, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Pyridines, Pyrimidines, Sorafenib